Insight Molecular Diagnostics Inc. (IMDX) Stock Price & Analysis

Insight Molecular Diagnostics Inc. (IMDX) rose 0.24% to USD 4.13 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.

IMDX last closed at USD 4.13; the session ranged USD 3.99–4.18 on volume of 183,524 shares. Market capitalization is —, with a 52-week range of USD 2.4–8.51 (NCM). Source: Nexqual, September 8, 2026 at 07:36 UTC.

Key Statistics (as of September 8, 2026 at 07:36 UTC)

Technical Analysis (IMDX)

Nexqual's technical model rates IMDX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.

From Insight Molecular Diagnostics Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Foreign Privacy and Security Laws Similar health care and data privacy laws and regulations exist in Europe and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, including the General Data Protection Regulation ("GDPR"), which went into effect in May 2018.
• We have sought, and intend to continue to seek, appropriate patent protection for important and strategic components of our proprietary technologies by filing patent applications in the United States and certain foreign countries.
• We have built and acquired an intellectual property portfolio that we believe will enable us to gain share in well-established clinical and research markets.
• Within these categories, we have developed or are in the process of developing laboratory developed tests ("LDTs") that can be run at our Franklin, Tennessee laboratory, kitted research use only ("RUO") tests, and in vitro diagnostic ("IVD") kitted clinical tests that can be run by local labs.

Partnerships

• On February 20, 2026, we entered into a Specimen Collection Agreement with a national reference lab provider.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.